Supernus Pharmaceuticals (SUPN) Other Non-Current Liabilities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Other Non-Current Liabilities data on file, last reported at $206000.0 in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 97.24% year-over-year to $206000.0 in Q1 2026; TTM through Mar 2026 was $206000.0, a 97.24% decrease from a year earlier, with the FY2025 full-year figure at $22.2 million, changed N/A from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $206000.0, down from $22.2 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for SUPN reached as high as $53.7 million in Q3 2023 and fell as low as $206000.0 in Q1 2026.
• Historically, Other Non-Current Liabilities has averaged $16.8 million across 5 years, with a median of $8.7 million in 2023.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 449.58% in 2024 and fell as far as 99.25% in 2024.
• Year by year, Other Non-Current Liabilities stood at $8.7 million in 2022, then decreased by 26.12% to $6.4 million in 2023, then sank by 93.72% to $403000.0 in 2024, then surged by 5406.7% to $22.2 million in 2025, then tumbled by 99.07% to $206000.0 in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $206000.0 in Q1 2026, $22.2 million in Q4 2025, and $213000.0 in Q3 2025.